… treatment with transplanted fetal neural tissue, according to a controversial, almost two-decade study. As reported in … on the Unified Parkinson's Disease Rating Scale (UPDRS), a common measure of disease severity, climbed about 25 … up by the initial experiment, begun in the early 1990s, where a condition known as graft-induced dyskinesia (GID) …

… Tracey Mumford, senior associate director of research partnerships, is going to Boston to talk … they need. I’ve found that my work with pharmaceutical companies and biotechs is really a two-way street, where their needs and input drive some MJFF initiatives, …

… Drug development, from testing through approval, can take decades and billions of dollars. According to the Pharmaceutical Research and Manufacturers of America … NDA, the FDA then has 60 days to ensure the application is complete and ready for full review. If the application is …

… NY— The Michael J. Fox Foundation for Parkinson’s Research today announced approximately $2.5 million in total funding … the patient’s quality of life. Funded projects will address common and debilitating aspects of PD such as depression, dyskinesia (the uncontrollable movements that are …

… Life with Parkinson’s disease (PD) is shaped by myriad factors, including sexual orientation and gender identity which … living with PD. To connect with others for support and community, join the Parkinson’s Buddy Network .  If you’d … rather listen on the go, subscribe to the show on iTunes or wherever you get your podcasts. If you enjoyed what you …

… Objective/Rationale: Many of the symptoms of Parkinson’s disease are caused by the death of … Using novel cellular assays, we have discovered lead compounds that prevent the toxicity induced by alpha-synuclein. Our goal is …